Thunen Shelley B 4

What Happened

• Shelley B. Thunen, a director of AEON Biopharma, was granted 222,684 restricted stock units (RSUs) on June 17, 2026. The Form 4 reports the acquisition as an award (code A) with a reported acquisition price of $0 on the filing.

Key Details

• Transaction date: 2026-06-17 (Grant of RSUs)
• Reported acquisition price on Form 4: $0 (RSUs, not a cash purchase)
• Number of RSUs granted: 222,684
• Shares owned after the transaction: Not disclosed in the provided filing
• Vesting: RSUs vest in full on the earlier of (i) one year after the grant date or (ii) the 2027 annual meeting of stockholders, subject to continued service (per footnote F1)
• Filing: Form 4 filed 2026-06-22 reporting the 2026-06-17 grant; timeliness of the filing is not indicated in the provided details

Context

• RSUs are a form of equity compensation that convert into shares if vesting conditions are met; they are not an immediate open-market purchase or sale. The $0 acquisition price on the Form 4 reflects the award reporting; the economic value depends on AEON’s share price when/if the RSUs vest and are settled.
• Awards to directors are common as part of compensation and do not by themselves indicate buy/sell intent. This is a grant (potential future ownership) rather than an immediate investment or liquidation.